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Abstract A new bioactive glass composition (CEL2) in
the SiO2–P2O5–CaO–MgO–K2O–Na2O system was tai-
lored to control pH variations due to ion leaching phe-
nomena when the glass is in contact with physiological
fluids. CEL2 was prepared by a traditional melting-
quenching process obtaining slices that were heat-treated to
obtain a glass-ceramic material (CEL2GC) that was char-
acterized thorough SEM analysis. Pre-treatment of
CEL2GC with SBF was found to enhance its biocompati-
bility, as assessed by in vitro tests. CEL2 powder was then
used to synthesize macroporous glass–ceramic scaffolds.
To this end, CEL2 powders were mixed with polyethylene
particles within the 300–600 lm size-range and then
pressed to obtain crack-free compacted powders (green).
This was heat-treated to remove the organic phase and to
sinter the inorganic phase, leaving a porous structure. The
biomaterial thus obtained was characterized by X-ray dif-
fraction, SEM equipped with EDS, density measurement,
image analysis, mechanical testing and in vitro evaluation,
and found to be a glass–ceramic macroporous scaffold with
uniformly distributed and highly interconnected porosity.
The extent and size-range of the porosity can be tailored by
varying the amount and size of the polyethylene particles.
Introduction
Since the discovery of bioglass by Hench et al. [1] in the
early 1970s, various types of ceramic, glass and glass–
ceramic have been proposed and used as bone replacement
biomaterials [2–4]. Specifically, these biomaterials have
found clinical applications as coating for prostheses, bone
filler, vertebral substitution and, in a porous form, as bone
substitutes [5–12]. Most of them are based on the SiO2–
P2O5–CaO–Na2O system. Bonding between bioactive glass
or glass–ceramic and the surrounding tissues takes place
through the formation of a hydroxyapatite layer, which is
very similar to the mineral phase of bone. When the bio-
active glass is placed in contact with physiological fluids,
this layer is formed through a complex ion-exchange
mechanism with the surrounding fluids, known as bioac-
tivity. This biologically-active layer of hydroxyapatite can
form on the surface of glasses having a wide compositional
range, and is considered as self by the surrounding living
tissue; its presence is widely recognized to be a sufficient
requirement for the implant to chemically bond with the
living bone. Kokubo et al. [13] proposed the Tris-buffered
simulated body fluid (SBF) for the in vitro study of bio-
active glass and glass–ceramic, since its ion concentration
is almost equal to that of human blood plasma. Since then,
in vitro tests in SBF have been widely used as preliminary
tests on new candidate materials showing bioactive prop-
erties.
The ion leaching phenomenon involves the exchange of
monovalent cations from the glass, such as Na+ or K+, with
H3O
+ from the solution, and thus causes an increase in the
pH of the solution. It is known that osteoblasts prefer a
slightly alkaline medium (7.8) [14, 15], but it is also known
that severe changes in pH can inhibit osteoblast activity
and cause cell necrosis or apoptosis [16–18].
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A new glass composition, named CEL2, was thus tai-
lored, with the goal of avoiding large pH changes by giving
the glass a lower monovalent oxide content (less than
20 mol%) and a slightly higher P2O5 content (3 mol%)
compared to commercial bioactive glasses. Preliminary
in vitro testing with osteoblast-like cells was carried out on
the proposed glass, and it was also pre-treated in SBF for
1 week as a further control of pH variations, as has been
proposed [18]. CEL2 was also used to prepare macropor-
ous scaffolds for possible use as bone substitutes, through
the burning-out method, described elsewhere [19]. This
method involves the use of an organic phase as pore for-
mer, which is mixed with inorganic particles (CEL2 in this
case) and then pressed, to obtain green, which is heat-
treated to remove the organic phase and to sinter the
inorganic phase.
Materials and methods
CEL2GC slice preparation
A new bioactive glass belonging to the system SiO2–P2O5–
CaO–MgO–Na2O–K2O was prepared. Its molar composi-
tion was selected so as to maximize bioactivity and bio-
compatibility, while avoiding undesired effects due to pH
changes caused by the ion leaching phenomenon.
The synthesized glass, named CEL2, has the following
molar composition: 45% SiO2, 3% P2O5, 26% CaO, 7%
MgO, 15% Na2O, 4% K2O, with a 4:1 Na2O/K2O ratio.
The glass was prepared by melting reagent-grade reactants
in a platinum crucible at 1400 C for 1 h; the melt was
poured onto a copper sheet to obtain bars, which were
annealed at 500 C for 12 h to release internal stresses. The
bars were then cut into slices.
The molten glass was also poured into water to obtain a
frit that was subsequently ball-milled to obtain powder.
CEL2 powder was characterized through differential ther-
mal analysis (DTA7 Perkins Elmer) to assess its charac-
teristic temperatures.
CEL2 slices were heat-treated at 950 C for 3 h to ob-
tain glass–ceramic samples (CEL2GC) for purposes of
comparison with the scaffolds, described below. CEL2GC
slices were chemically etched using a 5 vol% 1:1 HF,
HNO3 solution to remove the amorphous phase and to
investigate the morphology and composition of the crys-
talline phases.
Complete characterization of CEL2GC crystalline pha-
ses was attained through XRD analyses (X’Pert Philips
Diffractometer), scanning electron microscopy (SEM Phi-
lips 525 M) and Energy Dispersive Spectroscopy (EDS).
The glass–ceramic bioactivity was studied by soaking
CEL2GC slices in 25 mL of SBF, a solution that simulates
the inorganic composition of human plasma [13]. In par-
ticular, CEL2GC slices were maintained at 37 C for
1 week to study the formation of a silica rich gel layer and
the precipitation of hydroxyapatite (HAp) microcrystals on
top of that layer. During the test, the solution was refreshed
every 48 h to simulate physiological fluid exchange. The
pH of the solution was measured daily to evaluate the
influence of ion exchange between the sample and SBF and
to verify its confinement within a ‘‘physiological range’’.
Scaffold preparation and characterization
CEL2 powders were used to synthesize scaffolds for bone
substitutions. For this purpose, CEL2 powder was mixed
with a thermally-degradable phase (polyethylene) of
appropriate size, the mixture was then pressed and heat-
treated to remove the organic phase and sinter CEL2
powders. Specifically, CEL2 powders were sieved through
106 lm mesh, and polyethylene (PE) particles in the 300–
600 lm size-range were used as pore formers.
CEL2 powders and PE particles were mixed in a
1:1 volume ratio and pressed at 160 MPa for 10 s to obtain
crack-free green bars of size 5 · 1.5 · 1.5 cm. The bars
were heat-treated at 950 C for 3 h, heating rate 5/min,
obtaining a macroporous glass–ceramic structure. The bars
were then cut into 1 · 1 · 1 cm sample cubes, which were
used to assess the compressive strength of the scaffolds; the
test was performed in triplicate. The scaffold microstruc-
ture was observed under the SEM to investigate porosity
and degree of sintering. The total porosity was studied in
triplicate on sample cubes using the following formula:
% P ¼ 1  Wm/Wthð Þ  100 ð1Þ
where Wm is the measured weight and Wth the theoretical
weight obtained by multiplying the density of the glass by
the volume of the sample. The scaffold porosity was also
investigated in triplicate through image analysis on cross-
sections, with a window size of about 3 mm · 2 mm.
Scaffold bioactivity was studied by soaking sample
cubes in SBF for 1 week, refreshing the solution every
48 h.
Biological tests
CEL2GC slices and CEL2GC slices pre-treated in SBF for
1 week were investigated to assess the influence of this
pre-treatment on the biological response. A human osteo-
blast cell line (MG-63) obtained from the American Type
Culture Collection (Rockville, MD, USA) was grown as a
confluent monolayer in MEM medium containing 2 mM L-
glutamine, 1% (v/v) antibiotic/antimycotic solution, 1 mM
sodium pyruvate, and 10% (v/v) FBS (fetal bovine serum)
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under an atmosphere of 5% CO2 and 95% air at 37 C. The
sterilized CEL2GC slices, pre-treated or not in SBF, were
preconditioned for 24 h with culture medium in multi-well
plates and used to grow MG-63 cells. After removing the
preconditioning medium, the cells were seeded
(10,000 cells/cm2) in multi-well plates containing the sli-
ces. Three and eight days after seeding the osteoblasts, the
medium as well as the slices were removed. The slices
were used to count the number of cells growing on them,
and to examine the morphology of cells on the slices.
Cell growth and viability
To count the cells present on them, slices were treated with
trypsin to detach cells; detached cells were harvested and
centrifuged at 600 · g for 10 min. The cells were counted
in a Burker chamber using a light microscope (Leitz,
Wetzlar, HM-LUX, Germany). To determine cell viability,
plasma-membrane integrity was checked microscopically
using the trypan blue exclusion test. Trypan blue exclusion
was evaluated on cells suspended in the presence of the dye
(0.8 mg/mL); 400 cells were counted for each sample and
the result expressed as percentage of trypan blue-positive
cells.
Morphological evaluation by SEM
After cell culture, the slices were rinsed four times in PBS
and fixed with 2.5% glutaraldehyde in 0.1 M phosphate
buffer, pH 7.4, for 30 min at 4 C. Dehydration was per-
formed with slow water replacement by a series of graded
ethanol solutions with final dehydration in absolute ethanol
before critical-point drying. A gold coating was then
sputtered onto the samples for SEM observations.
Results and discussion
The TGA trace of CEL2 showed the presence of two
exothermic peaks, implying the nucleation and growth of
two different crystalline phases during the sintering treat-
ment.
The use of CEL2 for the synthesis of macroporous
structures involves heat-treatment above the crystallization
temperature of CEL2 (Txx) and thus a glass–ceramic
structure was expected. In order to observe and evaluate
the crystalline phase morphology and composition, CEL2
slices were heat-treated at 950 C for 3 h obtaining glass–
ceramic slices (CEL2GC).
CEL2GC slices were chemically etched with HNO3/HF
5 vol% for 30 s to remove the residual amorphous phase to
better observe the crystalline phases.
Figure 1a depicts the morphology of the first crystalline
phase, which is tetragonal with sharp edges; the sur-
rounding phase is the etched amorphous matrix with its
typical indented aspect. Fig. 1b reports the EDS results for
the tetragonal phase which, as may be seen, consists of a
great amount of silicon, calcium and smaller quantities of
magnesium.
The second crystalline phase is shown in Fig. 1c, it is
needle shaped and the EDS results in Fig. 1d show that
mainly comprises silicon, calcium, and magnesium. The
Fig. 1 Characterization of
CEL2GC slices (a) rectangular
shaped phase; (b) EDS of a; (c)
needle shaped crystalline phase;
(d) EDS of the needle shape
crystalline phase of c
Fig. 2 Diffraction pattern of CEL2GC
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comparison between the two EDS results shows that the
tetragonal phase is richer in calcium and poorer in silicon
than the needle shaped phase. X-ray diffraction (X’Pert
Philips Diffractometer) was used to assess the glass–cera-
mic nature of CEL2GC and to identify the crystalline
structure of the two phases. The diffraction pattern ob-
tained is reported in Fig. 2: the amorphous halo has almost
disappeared and many diffraction peaks are present, as
usually occurs for glass–ceramic materials. Due to the
complex composition of the crystalline phases, correct
identification of the peaks was impossible and thus, on the
basis of the EDS analysis, we may only say that the two
phases are calcium–magnesium silicates of different com-
positions.
CEL2GC bioactivity was investigated by soaking
1 · 1 cm glass–ceramic slices in 25 mL of SBF, refreshing
the solution every 2 days; refreshing the solution is fre-
quently applied to more accurately simulate in vitro fluid
circulation in the body.
Figure 3a reports a micrograph of CEL2GC after
1 week of soaking in SBF: the surface is completely cov-
ered by globular agglomerates of microcrystalline HAp.
The EDS analysis confirmed that the entire surface was
completely covered with HAp, since only phosphorus and
calcium were detected, with a Ca/P ratio of 1.7. The layer
beneath the HAp crystals is a gel-like layer rich in silica:
the cracks that are visible are due to drying of this silica gel
layer, which is highly hydrated; such cracks are frequently
observed on bioactive surfaces after soaking in SBF.
X-ray diffraction analyses were carried out on CEL2GC
slices after soaking in SBF to support the SEM and EDS
observations. Figure 3c reports the obtained CEL2GC
diffraction pattern after 1 week of soaking in SBF: as can
be observed, only two very wide peaks were detected and
their diffraction angles correspond to crystalline HAp. The
absence of CEL2GC diffraction peaks after soaking in SBF
is evidence of the thickness and uniformity of the HAp
layer precipitated on the CEL2GC surface. The width of
the diffraction peaks detected confirmed the microcrystal-
line nature of the HAp crystals, which is typical of those
grown in vitro on the surface of bioactive materials. On
these bases, CEL2GC may be considered a highly bioactive
glass–ceramic.
The rate and amount of ion release, and the related pH
variation, when a glass–ceramic is placed in contact with
physiological fluids, are extremely important for its bio-
Fig. 3 Characterization of
CEL2GC slices after pre-
treatment in SBF (a) CEL2GC
after 1 week of soaking in SBF;
(b) EDS of the whole area of
micrograph a; (c) Diffraction
pattern of CEL2GC after
1 week in SBF
Fig. 4 pH variations induced by CEL2GC in SBF, refreshing the
solution every 2 days
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compatibility. It is known that osteoblasts prefer moder-
ately alkaline conditions, i.e. pH values close to 7.8, while
changes in pH cause severe damage to cell viability [16–
18]. CEL2 composition was tailored in light of this con-
sideration, in an attempt to control pH variations. The total
content of monovalent ions was thus kept below 20 mol%
and the P2O5 content was set at 3 mol%, which is higher
than most bioactive glasses reported in the literature.
pH variations were studied by soaking CEL2GC slices
in SBF for 1 week, refreshing the solution every 2 days.
Figure 4 reports the pH trend for CEL2GC during its
soaking in SBF. As can be observed, after 6 days of
soaking in SBF, the pH is stable at around 7.75, which may
be considered optimal for osteoblast adhesion and prolif-
eration. The biocompatibility of CEL2GC was studied
through biological tests using human osteoblast-like MG-
63. For this purpose, CEL2GC slices and CEL2GC slices
pre-treated in SBF for 1 week were tested, to determine
any differences between them and any benefits relating to
CEL2GC pre-treatment in SBF.
The cells grew better in CEL2GC slices pre-treated in
SBF than they did in untreated CEL2GC slices, cell
numbers increasing 3.5 fold between day 3 and day 8 of
culture in pre-treated slices, versus 2.6 fold in untreated
slices. Cell viability was the same in cells grown on both
types of slice (data not shown).
Differences between the two types of slices were also
investigated by SEM, determining cell morphology
(Fig. 5). Figure 5a shows a human osteoblast-like MG-63
cell on CEL2GC after 8 days of culture, and Fig. 5b, c the
same on slices pre-treated in SBF for 1 week. The better
adhesion and spread of osteoblasts on CEL2GC pre-treated
Fig. 5 Osteoblast morphology as assessed by SEM. Osteoblast
proliferation for 8 days on as done CEL2GC (a); osteoblast
proliferation for 8 days on CEL2GC after 1 week of pre-treatment
in SBF (b, c)
Fig. 6 Micrographs at SEM of a CEL2 scaffold cross-section (a);
magnification of a CEL2 scaffold pore (b)
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in SBF versus untreated slices is clear. Thus the response to
CEL2GC pre-treated in SBF for 1 week was biologically
more active than to CEL2GC as such. As may be seen,
CEL2GC released ions into the culture medium, since its
surface is irregular and etched. In the case of pre-treated
CEL2GC, during pre-treatment in SBF considerable ion
release occurred, leading to pH variations, chiefly in the
first 2 or 3 days of soaking in SBF, with pH values
reaching 8 (see Fig. 4). After 1 week of soaking, the
solution being refreshed every 2 days, the pH variation
reached a plateau at about 7.75, a level compatible with
good cellular activity. In this case, the surface is covered by
HAp crystals, as may be seen in Fig. 3, and cells anchor
themselves onto these agglomerates, making bridges be-
tween the HAp microcrystals (see Fig. 5).
CEL2 was used to prepare macroporous glass–ceramic
scaffolds. For this purpose, CEL2 powder sieved through
106 lm mesh was pressed with polyethylene particles in a
size range of 300–600 lm, to obtain crack-free green,
which was heat-treated to remove the organic phase and
sinter the glass particles. Porous scaffolds were success-
fully obtained using 50% of polyethylene and 50% of
CEL2 powder by volume. Figure 6a shows a cross-section
of the scaffold obtained, in which the presence of a small
number of macropores and diffuse microporosity may be
seen. Microporosity is a key factor for nutrient flow inside
the scaffold, and is also known to play a positive role on
proteins and cellular adhesion [20]. Figure 6b shows the
scaffold at higher magnification; the high degree of sin-
tering of the pore struts and the pore interconnection can be
observed. The scaffold porosity was investigated through
weight measurements using Eq. 1 obtaining a total porosity
of 48 ± 3 vol% The low standard deviation is a proof of
the reproducibility of the proposed method.
Image analysis studies were carried out on the scaffold
using a representative window size of a few mm2. An
example of the results obtained is shown in Fig. 7. Spe-
cifically, Fig. 7a reports a back-scattering micrograph of a
CEL2 scaffold cross-section and Fig. 7b reports the chosen
window for pore evaluation. As may be seen in Fig. 7a, the
pores are uniformly distributed along the cross-section and
there is uniform dispersed microporosity. Image analysis
showed an average pore size of 105 lm, across both mi-
cropores and macropores. Figure 7c is a histogram of the
pore size distribution, considering not the number of pores
but rather the area they occupy, which is directly related to
the scaffold capability to host blood vessel formation, cell
viability and nutrient flow in vivo. As may be seen, mac-
ropores in the range 100–500 lm account for most of the
pore area, similarly manner to what occurs in human tra-
becular bone. It is agreed [21–25] that 100 lm is the lower
size limit at which macropores enable a scaffold to provide
cell migration and vascularisation; thus it may be said that
the proposed scaffolds meet this requirement.
Fig. 7 Pore evaluation of
scaffolding. Selection of
window size (a), detection of
the open pores in the window
(b); histogram of pore size
distribution (c)
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A compressive strength of 7 ± 0.6 MPa was determined
for the sample cubes. This value is very similar to that of
human cancellous bone, which varies within 2–12 MPa. A
very low standard deviation was found, demonstrating the
good reproducibility of the scaffold synthesis process.
Figure 8 shows two micrographs of the scaffold surface
after 1 week of soaking in SBF. As can be observed in
Fig. 8a, the scaffold surface is covered by many globular
agglomerates that, as is visible at higher magnification
(Fig. 8b) are also present on the pore walls. EDS analyses
on the white agglomerates (data not reported) only showed
the presence of Ca and P.
Conclusions
CEL2 in its glass–ceramic form was found to be a bioactive
and highly compatible biomaterial. Pre-treatment in SBF
for 1 week was found to be effective for favoring cell
adhesion and proliferation. The good biological behavior of
CEL2GC pre-treated in SBF, compared to untreated
CEL2GC, was shown by the increased osteoblast prolif-
eration on pretreated slices, with formation of calcium
deposits. The number and size of the calcium deposits in-
creased with culture time, to a greater extent in pre-treated
slices than in untreated ones, demonstrating the higher
osteoblast activity in the presence of a surface covered with
HAp crystals.
CEL2 powders were successfully used to prepare scaf-
folds using the polymeric burning-out method: the pores
present a certain degree of interconnection and most are in
the 100–500 lm range, which is considered optimal for a
bone replacement.
The compressive strength of the scaffold (7 MPa) is in
the range of human trabecular bone and the low standard
deviation confirmed the reproducibility of the proposed
method.
Work is in progress on the use of CEL2 to prepare
scaffolds with the polymeric replication method in order to
obtain a pore structure closer to that of human bone, both in
terms of interconnection and pore-size distribution.
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